Long-Lasting Memory Needs New Myelin Formation

Post by D. Chloe Chung

What's the science?

Our experiences can be recorded in the brain and persist as long-lasting or “remote” memory, through a process called memory consolidation, in which neuronal networks are reorganized over time to structurally represent certain memories. While several neural circuits have been suggested to be potentially responsible for memory consolidation, we still do not fully understand what is happening at the cellular level when particular experiences become solidified as a remote memory. One hint we can find from past studies is that memory functions can be mediated by oligodendrocytes, glial cells that form an insulating fatty tissue called myelin that wraps around axons of the neurons to help efficient neuronal transmission. This week in Nature Neuroscience, Pan and colleagues show that freshly generated oligodendrocytes and their new myelin formation are highly important in consolidating fearful experiences as remote fear memory.

How did they do it?

To make mice in the study learn certain experiences and remember them, the authors used fear conditioning. Fear conditioning trains mice to associate a fearful stimulus like an electric foot shock to neutral cues such as a particular smell or noise. If the mice later freeze (out of fear) after simply being placed in the same chamber even without experiencing a foot shock, this indicates that the mice correctly learned to remember a fearful experience. In this study, right before the fear conditioning, mice were injected with a chemical that incorporates into DNA of dividing cells, so that cells that are newly formed after the injection can be readily identified. 

Brains of these mice were examined either a day or a month after fear learning to evaluate various changes in the brain at different timepoints. To further explore how important new myelin-forming oligodendrocytes are in storing fear memory, the authors used a genetically engineered mouse model that can be induced to stop the production of new oligodendrocytes at any desired timepoint. These transgenic mice underwent the same memory test to determine the effects of new myelin formation on memory consolidation. As another approach, the authors also used a drug called clemastine that can induce new myelin formation and tested how it can change the ability of fear-conditioned mice in recalling remote fear memory.

What did they find?

The authors first observed that mice that successfully learned a fearful experience produced cells with the potential to become oligodendrocytes in the medial prefrontal cortex (mPFC), one of the brain regions important in storing long-term memory. Over the course of several weeks, these cells further matured and became oligodendrocytes that can actively myelinate axons. Interestingly, the authors found that mice that were genetically inhibited to produce new oligodendrocytes, failed to effectively recall a fearful experience from a month ago, as they did not show freezing behaviors like normal mice. Since these transgenic mice were able to remember a fear experience that happened a day before, the authors speculated that new myelin formation is important specifically for the long-term storage of fear memory. Upon closely examining the cells in the genetically inhibited mice that cannot form new myelin, the authors found that neurons in the memory consolidation brain regions were not efficiently activated, as shown by greatly reduced expressions of immediate early genes that are normally activated with external stimuli. Mice injected with myelination-promoting clemastine showed remote fear memory that was significantly more persistent and stabilized than the control group. This observation, accompanied by increased expression of immediate early genes, suggests that new myelin formation can substantially preserve remote fear memory.

Myelin_img_Feb18.jpg

What’s the impact?

This study presents the first evidence that effective storage of fear memories over a long period of time requires newly generated oligodendrocytes that can provide fresh myelin for neurons. This study is particularly interesting as it showed that myelination, which has been thought to mostly occur during the early development of the brain, is, in fact, a very dynamic process that can critically help to preserve long-lasting memories in the adult brain. Findings from this study may ultimately provide useful insights in developing effective treatment options for neurological diseases like post-traumatic stress disorder (PTSD), a disorder associated with the abnormal, intense recall of fear memories.

Pan et al. Preservation of a remote fear memory requires new myelin formation. Nature Neuroscience (2020). Access the original scientific publication here.

A New Clinical Syndrome: Trigeminal Neuralgia Associated with a Brain Lesion

Post by Kasey Hemington

What's the science?

Trigeminal Neuralgia (TN) is an excruciatingly painful condition. Patients experience severe pain attacks in areas associated with the trigeminal nerve, which innervates the face. In some cases, TN is associated with demyelination (damage to myelin – a protective covering for the nerve) either due to compression of the trigeminal nerve itself or secondary to Multiple Sclerosis (MS-TN), which can cause demyelinating plaques in the brainstem. A few case studies have noted that some TN patients have lesions of the brainstem, but do not have Multiple Sclerosis. However, this unique patient sub-group has not been extensively studied. This week in PAIN, Tohyama and colleagues used magnetic resonance imaging (MRI) and clinical evidence to define a new syndrome: TN associated with solitary pontine lesion (SPL-TN; ‘pontine’ refers to the pons, a region of the brainstem)

How did they do it?

The authors examined clinical records and MRI brain scans for 481 TN patients who underwent neurosurgical TN treatment (commonly gamma knife surgery, a non-invasive type of surgery that uses beams of radiation). All patients underwent an anatomical MRI (T1-weighted), and a subset of patients also underwent a diffusion-weighted MRI. SPL-TN was defined based on an idiopathic TN diagnosis (e.g. TN not secondary to Multiple Sclerosis), a single lesion along the trigeminal nerve pathway, and no other brain lesions. To characterize the lesions, the authors used an anatomical MRI and mapped the lesion by hand in each patient before comparing lesion distribution and area across subjects. The authors hypothesized SPL-TN patients to be surgical treatment non-responders, and defined treatment non-response as having undergone three or more surgical procedures, or having undergone one surgical procedure without experiencing substantial pain relief. Lack of relief was defined as <75% pain reduction using an 11-point pain Numerical Rating Scale and a score of 4 or higher on the Barrow Neurological Institute Scale, which measures the frequency of medication use for pain control.

From diffusion-weighted MRI scans of the lesions, the authors calculated metrics including fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity, which reflect the brain’s white matter microstructure, neuroinflammation, myelination, and axonal integrity, respectively. To act as a healthy control group, the authors recruited healthy individuals, age- and sex-matched to SPL-TN patients for whom anatomical and diffusion-weighted MRI brain scans were available. The healthy control group underwent these same brain scans.

What did they find?

Upon reviewing the 481 TN patient records, the authors found 24 cases of SPL-TN. Eighteen of those patients had clinical follow-up information available post-surgery and it was determined that 17/18 of those patients did not respond to surgical treatment, suggesting non-response to surgical treatment is characteristic of SPL-TN. For these 17 patients (6 men, 11 women), lesions were mapped and found to be along the trigeminal pathway in the pons on the affected side of the brain in all cases. Overlap amongst patients was maximal in the trigeminal brainstem sensory nuclear complex. Diffusion-weighted MRI scans were available for 11 of the 17 patients, and were used to compare the lesions on the affected side of the brain in SPL-TN patients versus a) the same region on the non-affected side and b) the brains of 11 healthy controls. No differences in fractional anisotropy, mean diffusivity, axial diffusivity, or radial diffusivity were found between the non-affected side in patients and healthy controls, while lower fractional anisotropy and higher mean diffusivity and radial diffusivity were found on the affected side versus the non-affected sides and healthy controls. Additionally, axial diffusivity was higher on the affected side versus the non-affected side. These findings indicate abnormal white matter properties in SPL-TN lesions.

FA = Fractional Anisotropy, MD = Mean Diffusivity, RD = Radial Diffusivity, AD = Axial Diffusivity

FA = Fractional Anisotropy, MD = Mean Diffusivity, RD = Radial Diffusivity, AD = Axial Diffusivity

SPL-TN patient lesions were also compared to lesions in a group of 17 MS-TN patients, age-matched for the age of TN onset. In MS-TN patients, between 1-5 lesions could be found along the trigeminal nerve pathway. No differences between groups were found in diffusivity metrics when comparing whole lesions. However, when the analysis was restricted precisely to the trigeminal brainstem tract within a lesion, lower fractional anisotropy, and higher axial diffusivity, mean diffusivity, and radial diffusivity were found in SPL-TN lesions versus MS-TN lesions.

What's the impact?

This study is the first to define SPL-TN, a subtype of TN characterized by non-response to surgical treatment and a single brainstem lesion commonly in the trigeminal nucleus. These lesions have changes in diffusivity metrics that characterize abnormal white matter microstructure. The identification of SPL-TN will guide specialized treatment plans for these patients.

Tohyama et al. Trigeminal neuralgia associated with a solitary pontine lesion. PAIN (2020). Access the original scientific publication here.

Exploring the Long-Term Effects of Psychedelics on the Brain

Post by Flora Moujaes 

What's the science? 

Psilocybin, the psychoactive compound in magic mushrooms, has recently proven an effective treatment for depression, anxiety, tobacco addiction, and alcohol use disorder. Treatment with psilocybin can have long-lasting effects: 1-3 psilocybin sessions can lead to a reduction in clinical symptoms that lasts for up to one year. We still don’t fully understand the psychological and neural mechanisms that underlie psilocybin’s therapeutic effects. Molecular studies have shown that psilocybin is a serotonin 2A/5-HT2A partial agonist, while therapeutic studies have indicated that psilocybin exerts its clinical effects by reducing negative affect and increasing positive affect. The reduction in negative affect may be linked to the amygdala, the brain region responsible for tracking the salience of the stimuli in the environment. Functional magnetic resonance imaging (fMRI) studies have shown that psilocybin reduces amygdala activity when viewing negative stimuli. This week in Scientific Reports, Barrett et al. use fMRI to explore the long-term effects of psilocybin on emotional and brain plasticity in order to better leverage it as a clinical tool. 

How did they do it?

To explore the long-term effects of psilocybin, the researchers administered a single high dose of psilocybin (25mg/70kg) to twelve healthy volunteers in an open-label within-subjects pilot study. To investigate if psilocybin could lead to an enduring increase in positive affect and decrease in negative affect, a battery of self-report state and trait measures was completed one day before, one week after, and one month after psilocybin administration. Responses were then compared between time-points. At each time-point, in order to determine whether psilocybin could lead to an enduring change in neural response to emotional stimuli, participants also took part in an fMRI session in which they completed three emotion-processing tasks. fMRI analysis of the emotion-processing tasks focused on the amygdala as a key region of interest. Finally, to determine whether psilocybin could lead to an enduring change in brain plasticity, participants’ resting-state fMRI data were also collected at each time-point. Functional connectomes were then compared between timepoints.

What did they find?

Long-term behavioural effects of psilocybin on emotions: Behavioural measures indicated that one-week post-psilocybin there was a reduction in negative affect and an increase in positive affect. One month post-psilocybin, the reduction in negative affect returned to baseline levels, while positive affect remained elevated. Ratings of trait anxiety were also reduced one-month post-psilocybin, despite showing no significant reduction one-week post-psilocybin. 

Long-term neural effects of psilocybin on emotions: Analyses of the fMRI data revealed that psilocybin led to reduced amygdala response to facial affect stimuli one-week post-psilocybin, however, this change was not sustained after one month. Overall, these results suggest that acute psilocybin administration leads to shifts in emotional affect, and the neural correlates of affective processing, which may endure one month later. fMRI data also showed that psilocybin resulted in increased dorsal lateral prefrontal and medial orbitofrontal cortex activity in response to emotionally conflicting stimuli after one week, and increased somatosensory cortex and fusiform gyrus activity in response to emotionally conflicting stimuli after one month. This indicates that psilocybin may also increase the top-down control of emotional processes, which may have a modulatory effect on the amygdala.

psilocybin_quote_Feb18.png

Long-term effects of psilocybin on brain plasticity: Global increases in functional connectivity were found both one week and one-month post-psilocybin. The increase in functional connectivity strength that was observed indiscriminately across multiple networks may reflect a domain-general cortical plasticity process that supports the observed changes in affective processing. 

What's the impact? 

Overall this study shows that despite the fact that the half-life of psilocybin is roughly 3 hours, psilocybin induced behavioural and neural changes were seen one-week and one-month post-psilocybin administration. This indicates that acute psilocybin may lead to a dynamic and neuroplastic period that lasts for a number of weeks, during which the neural processing of affective stimuli is altered. These findings also help explain psilocybin’s therapeutic effects: reduction of negative affect may undermine ruminative processes that contribute to depression and explain the antidepressant effects of psilocybin. Studies that utilize a larger sample size and placebo-controlled design are needed to explore this key neuroplastic period following acute psilocybin administration. 

Barrett et al. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports (2020). Access the original scientific publication here.